Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immutep’s SEC filings can feel like lab notebooks written in legalese. Hundreds of pages detail LAG-3 science, clinical trial outlays and milestone payments, making it hard to pinpoint what really moves the share price. Stock Titan’s AI-powered summaries cut through that complexity, surfacing cash-runway figures, patent expirations and partnership revenues in seconds. If you have ever searched “Immutep SEC filings explained simply” or wondered how to track “Immutep insider trading Form 4 transactions,” this page is built for you.
Every disclosure uploads in real time from EDGAR—annual reports, 10-Q quarterly earnings, sudden 8-K trial updates, and S-3 capital raise documents. Our platform links each form to questions investors actually ask:
- “Immutep quarterly earnings report 10-Q filing” highlights R&D spend vs. cash on hand.
- “Immutep annual report 10-K simplified” maps upcoming clinical milestones.
- “Immutep proxy statement executive compensation” breaks down option grants and incentives.
- “Immutep 8-K material events explained” flags trial readouts and FDA interactions.
- “Immutep executive stock transactions Form 4” provides real-time alerts on insider moves.
Behind each link, you’ll find concise AI commentary, ratio analysis and historical context so you can compare quarter-over-quarter progress or monitor dilution risk. Whether you’re conducting an “Immutep earnings report filing analysis,” checking “Immutep Form 4 insider transactions real-time,” or simply “understanding Immutep SEC documents with AI,” you’ll save hours and make better-informed decisions. Complex biotech disclosures, finally clear.
Immutep Limited furnishes a Form 6-K that includes an exhibit titled “Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study.” This indicates the company is providing investors with a positive clinical update on IMP761, which it describes as a first-in-class LAG-3 agonist antibody being studied for autoimmune diseases in a Phase I trial. The detailed results and implications of this Phase I study are contained in the attached exhibit, which is referenced but not reproduced here.
Immutep Limited, an Australia-based biotechnology company, has filed a report indicating it will present new data from its AIPAC-003 Phase II study at the 2025 San Antonio Breast Cancer Symposium. This presentation highlights ongoing clinical development work in breast cancer and suggests continued progress in evaluating its experimental therapy in this indication.
Immutep Limited furnished a Form 6-K noting it received an A$4.6 million research and development tax incentive from the French Government. This inflow reflects government support tied to the company’s R&D activities.
The update is administrative in nature but adds cash to the business, as disclosed in the exhibit titled “Immutep Receives A$4.6 million R&D Tax Incentive from French Government.”
Immutep Limited filed its annual report on Form 20-F, outlining ongoing development of LAG‑3 immunotherapies and continued operating losses. The company reported a net loss of A$61.4 million for the fiscal year ended June 30, 2025, compared with A$42.7 million in 2024. Shares outstanding were 1,460,389,575 as of June 30, 2025. Its ADSs, each representing 10 ordinary shares, trade on Nasdaq as IMMP.
Immutep has no products approved for sale and is focused on clinical candidates including eftilagimod alfa (efti), IMP761, and partnered programs such as IMP701 (ieramilimab) with Novartis. The company has collaboration and supply agreements with Merck & Co. for pembrolizumab combination trials (Phase II and Phase III) and with Merck KGaA/Pfizer for avelumab (Phase I), and a regional license with EOC Pharma in China.
Management expects further losses as clinical activities expand and notes reliance on third‑party manufacturers, trial enrollment challenges, regulatory risks, and the need for additional financing. Financial statements are prepared under IFRS and presented in Australian dollars.
Immutep Limited furnished a Form 6-K noting that the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma met its primary endpoint, with data presented at the ESMO Congress 2025.
The update is provided via Exhibit 99.1. Additional clinical details would be contained in the exhibit presentation materials.
Immutep Limited furnished a Form 6-K reporting an exhibit titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.” The notice identifies Exhibit 99.1 as the related material and is dated October 13, 2025.
FAQ
What is the current stock price of Immutep (IMMP)?
What is the market cap of Immutep (IMMP)?
